SEER vs. AKYA, BNGO, RPID, NAUT, PACB, SCLX, ACET, RGLS, INCR, and RPTX
Should you be buying Seer stock or one of its competitors? The main competitors of Seer include Akoya Biosciences (AKYA), Bionano Genomics (BNGO), Rapid Micro Biosystems (RPID), Nautilus Biotechnology (NAUT), Pacific Biosciences of California (PACB), Scilex (SCLX), Adicet Bio (ACET), Regulus Therapeutics (RGLS), InterCure (INCR), and Repare Therapeutics (RPTX). These companies are all part of the "medical" sector.
Seer (NASDAQ:SEER) and Akoya Biosciences (NASDAQ:AKYA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, community ranking, dividends, valuation, institutional ownership and earnings.
Akoya Biosciences has a net margin of -65.53% compared to Seer's net margin of -529.52%. Seer's return on equity of -20.69% beat Akoya Biosciences' return on equity.
75.2% of Seer shares are held by institutional investors. Comparatively, 79.4% of Akoya Biosciences shares are held by institutional investors. 15.0% of Seer shares are held by insiders. Comparatively, 7.3% of Akoya Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Seer has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, Akoya Biosciences has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500.
Seer presently has a consensus target price of $7.00, indicating a potential upside of 224.07%. Akoya Biosciences has a consensus target price of $7.79, indicating a potential upside of 168.47%. Given Seer's higher probable upside, equities analysts plainly believe Seer is more favorable than Akoya Biosciences.
Akoya Biosciences has higher revenue and earnings than Seer. Akoya Biosciences is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.
In the previous week, Akoya Biosciences had 2 more articles in the media than Seer. MarketBeat recorded 14 mentions for Akoya Biosciences and 12 mentions for Seer. Seer's average media sentiment score of -0.09 beat Akoya Biosciences' score of -0.16 indicating that Seer is being referred to more favorably in the media.
Akoya Biosciences received 25 more outperform votes than Seer when rated by MarketBeat users. Likewise, 60.87% of users gave Akoya Biosciences an outperform vote while only 14.29% of users gave Seer an outperform vote.
Summary
Akoya Biosciences beats Seer on 9 of the 17 factors compared between the two stocks.
Get Seer News Delivered to You Automatically
Sign up to receive the latest news and ratings for SEER and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SEER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
